To evaluate whether T1 contrast-enhanced (T1CE) tumour volume and apparent diffusion coefficient (ADC) metrics on MRI predict survival in PCNSL patients treated with MATRix chemotherapy.
Approach:
Patient Cohort: Sixty-five patients with newly diagnosed PCNSL treated with MATRix were included, with pre-treatment MRI performed for volumetric and diffusion analysis.
MRI Acquisition: MR images were obtained using standardized imaging sequences across multiple centers, ensuring sufficient inter-scanner ADC reproducibility.
T1CE Tumour Segmentation: T1CE tumour volumes were manually segmented and verified by a neuroradiologist, focusing on enhancing regions on post-contrast T1-weighted images.
ADC Measurements: Regional ADC measurements were taken at the earliest available MRI timepoint by a board-certified neuroradiologist.
Key Findings:
None of the imaging variables, including T1CE tumour volume and ADC measures, were significantly associated with overall survival (OS) or progression-free survival (PFS).
Baseline T1CE and diffusion biomarkers did not predict survival in MATRix-treated PCNSL patients.
Interpretation:
Limitations:
The study is retrospective and may have inherent biases.
The sample size of 65 patients may limit the generalizability of the findings.
Variability in treatment cycles and consolidation with ASCT among patients could affect outcomes.
